Literature DB >> 11801502

Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation.

David J Keegan, Gerd Geerling, John P Lee, Glen Blake, J Richard Collin, Gordon T Plant.   

Abstract

AIM: To investigate the potential of botulinum toxin A for treating hyperlacrimation.
METHODS: Three patients with unilateral symptoms of hyperlacrimation (diagnosed as "crocodile tearing") and one patient with a submandibular salivary gland transplant (SMGT) were studied. Tear production was quantified in the resting and stimulated (chewing or following exercise) state, using Schirmer's test and tear clearance. Lacrimal scintigraphy was used to assess outflow. Intraglandular injections (for patients with "crocodile tears") or periglandular injections (for the SMGT patient) of Dysport were administered in divided doses.
RESULTS: Two of the three eyes with reported gustatory lacrimation had a higher Schirmer test result than their fellow eye following gustatory stimulation. Scintigraphy, with and without stimulation, confirmed a patent drainage system in these patients. The other patient demonstrated a functional obstruction to tear flow. After treatment patients with confirmed gustatory lacrimation and the SMGT patient had a marked reduction in tearing at 2 weeks. This effect lasted 3-4 months. There was no demonstrable improvement in the patient with epiphora secondary to functional obstruction. Two patients who had received intraglandular injections developed a ptosis, which resolved spontaneously.
CONCLUSIONS: This study illustrates that gustatory lacrimation is a difficult diagnosis. In post-facial nerve palsy a functional element must always be considered. However, in confirmed hyperlacrimation botulinum toxin treatment is effective but side effects may occur.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11801502      PMCID: PMC1770990          DOI: 10.1136/bjo.86.1.43

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  12 in total

1.  Autonomic dysfunction in botulism B: a clinical report.

Authors:  G Jenzer; M Mumenthaler; H P Ludin; F Robert
Journal:  Neurology       Date:  1975-02       Impact factor: 9.910

Review 2.  Therapeutic uses of botulinum toxin.

Authors:  J Jankovic; M F Brin
Journal:  N Engl J Med       Date:  1991-04-25       Impact factor: 91.245

3.  Botulinum toxin in the therapy of gustatory sweating.

Authors:  A Schulze-Bonhage; M Schroder; A Ferbert
Journal:  J Neurol       Date:  1996-02       Impact factor: 4.849

4.  Botulinum toxin decreases salivation from canine submandibular glands.

Authors:  C M Shaari; B L Wu; H F Biller; S K Chuang; I Sanders
Journal:  Otolaryngol Head Neck Surg       Date:  1998-04       Impact factor: 3.497

5.  Clostridium botulinum toxins: nature and preparation for clinical use.

Authors:  J Melling; P Hambleton; C C Shone
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

6.  Frey's syndrome: treatment with botulinum toxin.

Authors:  C Drobik; R Laskawi
Journal:  Acta Otolaryngol       Date:  1995-05       Impact factor: 1.494

7.  Transplantation of the autologous submandibular gland for most severe cases of keratoconjunctivitis sicca.

Authors:  G Geerling; P Sieg; G O Bastian; H Laqua
Journal:  Ophthalmology       Date:  1998-02       Impact factor: 12.079

8.  Treatment of Frey's syndrome (gustatory sweating) and 'crocodile tears' (gustatory epiphora) with purified botulinum toxin.

Authors:  R J Hofmann
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2000-07       Impact factor: 1.746

9.  "Paralytic' secretion after parasympathectomy of rabbit submandibular glands includes a cholinergic component.

Authors:  J R Garrett; K Kyriacou
Journal:  Q J Exp Physiol       Date:  1988-09

10.  Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy.

Authors:  B Boroojerdi; A Ferbert; M Schwarz; H Herath; J Noth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-07       Impact factor: 10.154

View more
  17 in total

1.  [Long-term follow-up after autologous submandibular gland transplantation in scarring keratoconjunctivitis with absolute dry eyes].

Authors:  C Schröder; S G Hakim; J R O Collin; P Sieg; G Geerling
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

Review 2.  Long term efficacy and safety of botulinum toxin A injection for crocodile tears syndrome.

Authors:  D E Barañano; N R Miller
Journal:  Br J Ophthalmol       Date:  2004-04       Impact factor: 4.638

3.  [Botulinum toxin for ocular complications after facial palsy].

Authors:  E Torres Suárez
Journal:  Ophthalmologe       Date:  2012-03       Impact factor: 1.059

4.  [Botulinum toxin for the treatment of secretory disorders of the head and neck area].

Authors:  A Steffen
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

5.  Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system.

Authors:  Dirk Dressler
Journal:  J Neurol       Date:  2012-08-10       Impact factor: 4.849

Review 6.  Lacrimal gland botulinum toxin injection for epiphora management.

Authors:  Johnathan Jeffers; Katherine Lucarelli; Sruti Akella; Pete Setabutr; Ted H Wojno; Vinay Aakalu
Journal:  Orbit       Date:  2021-08-15

Review 7.  [Current and experimental treatment approaches for neurotrophic keratopathy].

Authors:  J Alder; S Mertsch; J Menzel-Severing; G Geerling
Journal:  Ophthalmologe       Date:  2019-02       Impact factor: 1.059

8.  Noncosmetic periocular therapeutic applications of botulinum toxin.

Authors:  Pelin Kaynak-Hekimhan
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

9.  Facial nerve palsy: providing eye comfort and cosmesis.

Authors:  Adel H Alsuhaibani
Journal:  Middle East Afr J Ophthalmol       Date:  2010-04

10.  Intraglandular injection of botulinum toxin a reduces tear production in rabbits.

Authors:  Anna M Demetriades; Ilya M Leyngold; Sam D'Anna; Allen O Eghrari; Dave G Emmert; Michael P Grant; Shannath L Merbs
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2013 Jan-Feb       Impact factor: 1.746

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.